• Prostate Cancer Treatment

    Zytiga (Arbiraterone), Xtandi (MDV3100), Jevtana (Cabazitaxel), Provenge (Sipuleucel-T), Taxotere (Docetaxel)

  • Lung Cancer Treatment

    Xalkori (Crizotinib), Alimta (Pemetrexed Disodium), Iressa (Gefitinib), Taxol (Paclitaxel), Tarceva (Erlotinib Hydrochloride)

  • Kidney Cancer Treatment

    Sutent (Sunitinib), Nexavar (Surafenib), Votrient (Pazopanib), Afinitor (Everolimus), Inlyta (Axitinib)

  • Colon Cancer Treatment

    Stivarga (Regorafenib), Avastin (Bevacizumab), Erbitux (Cetuximab), Vectibix (Panitumumab), Wellcovorin (Leucovorin Calcium), Zaltrap (Ziv-Aflibercept)

  • Breast cancer Treatment

    Perjeta (pertuzumab), Afinitor (Everolimus), Herceptin (Trastuzumab), Tykerb (Lapatinib Ditosylate), Xeloda (Capecitabine)

Contact Cancer Treatment Meds
  • Call toll free from the US USA (Toll Free) :1-800-805-7239 Call toll free from the US PRC: 10-800-713-1275(N), 10-800-130-1235(S)
  • Call toll free from the US Aussie: +61-03-9013-3771 Call toll free from the US Бесплатный номер для звонков из России :8-800-100-6943
Contact Us Online now
View as
Sort by
Display per page

Buy Votrient

Buy brand name Votrient 200 mg or 400 mg 28 Tablets
Call for pricing

Votrient effectiveness:

Votrient effectiveness has been reported by a number of research studies including clinical trials. Votrient effectiveness is usually noticed in terms of response rate, progression free survival and tumor shrinkage and these properties are well documented in favor of Votrient.

Votrient benefits:

Votrient benefits include a good degree of tolerability, relatively less side effects especially chances for cytopenia are quite low with Votrient, better response rate, and increased progression free survival. One of the important Votrient benefits is oral administration which makes its treatment easier.

Votrient results:

Votrient results characterize a significant prolonging of progression free survival in all patients. Other important features of Votrient results included more robust response in treatment naïve patients as compared to the patients which previously undergone cytotoxic therapy .

Votrient efficacy:

Clinical activity of Votrient depicting Votrient efficacy has been noticed in kidney, thyroid, breast, cervical, liver, lung, prostate, and colorectal cancer. Votrient efficacy has also been observed against melanoma and glioblastoma. Though, it has sought approval for kidney cancer, clinical trials are underway for several other types .

Votrient response rate:

Votrient response rate was assessed in the Phase III of clinical trials that led to the approval of this drug. This trial was based on the 435 renal cell carcinoma patients. Votrient response rate noted in this study was 32% for treatment naïve patients with a median time of 58.7 weeks .